Autopsy report · NCT04464967

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

“Trial not initiated”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

NKGen Biotech, Inc.

Sponsor type

Industry

Conditions

Advanced Solid Tumor; Metastatic Cancer; HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER-2 Protein Overexpression; Esophageal Cancer

Interventions

SNK01; Trastuzumab; Cetuximab

Participants

0

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.